| Pharmaceutical Information |
| Drug Name |
Oritavancin |
| Drug ID |
BADD_D01623 |
| Description |
Oritavancin is a glycopeptide antibiotic used for the treatment of skin infections. It was developed by The Medicines Company (acquired by Novartis).[L12858] Oritavancin was initially approved by the FDA in 2014 and formulated to combat susceptible gram-positive bacteria that cause skin and skin structure infections. It boasts the option of single-dose administration and has been proven as non-inferior to a full course of [vancomycin] therapy.[A39384,A193482,L8492]
On March 12, 2021 the FDA approved Kimyrsa, a complete course of therapy in a single, 1 hour 1200 mg infusion.[L32634] Orbactiv, the other FDA approved oritavancin product, is administered over a 3 hour infusion and contains a lower dose of 400 mg. Marketed by Melinta Therapeutics, Kimyrsa offers effective and time-efficient treatment for skin and skin structure infections.[L32629] |
| Indications and Usage |
Investigated for use/treatment in bacterial infection and skin infections/disorders. |
| Marketing Status |
Prescription |
| ATC Code |
J01XA05 |
| DrugBank ID |
DB04911
|
| KEGG ID |
D05271
|
| MeSH ID |
C100708
|
| PubChem ID |
16136912
|
| TTD Drug ID |
D02IBU
|
| NDC Product Code |
68225-051; 70842-140 |
| Synonyms |
oritavancin | LY 333328 | LY-333328 | LY333328 | Orbactiv |
|
| Chemical Information |
| Molecular Formula |
C86H97Cl3N10O26 |
| CAS Registry Number |
171099-57-3 |
| SMILES |
CC1C(C(CC(O1)OC2C3C(=O)NC(C4=C(C(=CC(=C4)O)O)C5=C(C=CC(=C5)C(C(=O)N3)NC(=O)C6C7=
CC(=C(C(=C7)OC8=C(C=C2C=C8)Cl)OC9C(C(C(C(O9)CO)O)O)OC1CC(C(C(O1)C)O)(C)NCC1=CC=C
(C=C1)C1=CC=C(C=C1)Cl)OC1=C(C=C(C=C1)C(C(C(=O)NC(C(=O)N6)CC(=O)N)NC(=O)C(CC(C)C)
NC)O)Cl)O)C(=O)O)(C)N)O |
| Chemical Structure |
|
|
| ADR Related Proteins Induced by Drug |
| ADR Term |
Protein Name |
UniProt AC |
TTD Target ID |
PMID |
| Not Available | Not Available | Not Available | Not Available | Not Available |
|
| ADRs Induced by Drug |
|
|
